398 related articles for article (PubMed ID: 32653469)
1. Thromboinflammation in COVID-19 acute lung injury.
Mitchell WB
Paediatr Respir Rev; 2020 Sep; 35():20-24. PubMed ID: 32653469
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET).
Marietta M; Ageno W; Artoni A; De Candia E; Gresele P; Marchetti M; Marcucci R; Tripodi A
Blood Transfus; 2020 May; 18(3):167-169. PubMed ID: 32281926
[No Abstract] [Full Text] [Related]
3. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
[TBL] [Abstract][Full Text] [Related]
4. Immune-Mediated Coagulopathy in COVID-19 Infection.
Vadasz Z; Brenner B; Toubi E
Semin Thromb Hemost; 2020 Oct; 46(7):838-840. PubMed ID: 32877959
[No Abstract] [Full Text] [Related]
5. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
Iba T; Connors JM; Levy JH
Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.
Gu SX; Tyagi T; Jain K; Gu VW; Lee SH; Hwa JM; Kwan JM; Krause DS; Lee AI; Halene S; Martin KA; Chun HJ; Hwa J
Nat Rev Cardiol; 2021 Mar; 18(3):194-209. PubMed ID: 33214651
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
Thromb Haemost; 2020 Jul; 120(7):1004-1024. PubMed ID: 32473596
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
Ahmed S; Zimba O; Gasparyan AY
Clin Rheumatol; 2020 Sep; 39(9):2529-2543. PubMed ID: 32654082
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 coagulopathy: an evolving story.
The Lancet Haematology
Lancet Haematol; 2020 Jun; 7(6):e425. PubMed ID: 32470428
[No Abstract] [Full Text] [Related]
10. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19.
Hashemi A; Madhavan MV; Bikdeli B
Semin Thromb Hemost; 2020 Oct; 46(7):789-795. PubMed ID: 32820478
[No Abstract] [Full Text] [Related]
12. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
13. Long lasting hypercoagulability after subclinical COVID-19.
Ferroli P; Villa C; Ciuffi A; Gubertini G; Broggi M
J Thromb Thrombolysis; 2020 Nov; 50(4):822-824. PubMed ID: 32757154
[No Abstract] [Full Text] [Related]
14. COVID-19 and Hypercoagulable State: A New Therapeutic Perspective.
Nascimento JHP; Gomes BFO; Carmo Júnior PRD; Petriz JLF; Rizk SI; Costa IBSDS; Lacerda MVG; Bacal F; Hajjar LA; Oliveira GMM
Arq Bras Cardiol; 2020 Jun; 114(5):829-833. PubMed ID: 32491074
[No Abstract] [Full Text] [Related]
15. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.
Miesbach W; Makris M
Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459
[TBL] [Abstract][Full Text] [Related]
16. Coagulopathy of Coronavirus Disease 2019.
Iba T; Levy JH; Levi M; Connors JM; Thachil J
Crit Care Med; 2020 Sep; 48(9):1358-1364. PubMed ID: 32467443
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.
Amgalan A; Othman M
Platelets; 2020 Aug; 31(6):740-745. PubMed ID: 32456506
[TBL] [Abstract][Full Text] [Related]
18. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
Saini KS; Lanza C; Romano M; de Azambuja E; Cortes J; de Las Heras B; de Castro J; Lamba Saini M; Loibl S; Curigliano G; Twelves C; Leone M; Patnaik MM
Br J Cancer; 2020 Sep; 123(5):694-697. PubMed ID: 32572174
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 update: Covid-19-associated coagulopathy.
Becker RC
J Thromb Thrombolysis; 2020 Jul; 50(1):54-67. PubMed ID: 32415579
[No Abstract] [Full Text] [Related]
20. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia.
Costanzo L; Palumbo FP; Ardita G; Antignani PL; Arosio E; Failla G;
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):711-716. PubMed ID: 32561465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
